We recently published a list of the 10 Best Performing Pharma Stocks So Far in 2025. In this article, we are going to take a ...
Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | ...
EST Cathie Wood’s ARK Investment buys 171K shares of Beam Therapeutics (BEAM) todayDiscover the Best Stocks and Maximize Your Portfolio: ...
Ark Invest, through its ARK Fintech Innovation ETF ARKF -5.46% + Free Alerts , bought 162,143 shares of Nu Holdings Ltd. This marks a significant investment in the fintech company, reflecting Ark’s ...
NASDAQ BEAM opened at $25.59 on Monday. Beam Therapeutics has a 52 week low of $20.84 and a 52 week high of $49.50. The business’s fifty day simple moving average is $26.50 and its 200-day ...
While it may not be enough for some shareholders, we think it is good to see the Beam Therapeutics Inc. (NASDAQ:BEAM) share price up 19% in a single quarter. But over the last three years we've ...
2025年2月20日， Beam Therapeutics（BEAM）披露1笔公司内部人交易情况。高管Cavanagh Bethany J于2025年2月18日卖出6287股。 2025年2月20日 高管 Cavanagh Bethany J 2025年2月18日 卖出 6287 35.00 22.00万 2025年2月19日 高管 Bellon Christine 2025年2月14日 卖出 1 ...
In a move that caught the attention of investors, ARK significantly increased its holdings in Beam Therapeutics Inc (NASDAQ:BEAM), purchasing a total of 170,778 shares valued at approximately $5. ...
Cathie Wood的ARK ETF基金公布了2025年2月20日星期四的每日交易数据，显示其继续专注于基因组创新领域，并对其科技和机器人投资组合进行调整。引起投资者关注的是，ARK通过其ARKK和ARKG基金大幅增持了Beam Therapeutics Inc（NASDAQ:BEAM）的持股，总计购入170,778股，价值约$5.82million。
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback